A Study of LY3502970 in Healthy Participants
Фаза 1
Завершено
NCT03929744
| Заболевание | Healthy |
|---|
| Фаза | Фаза 1 |
|---|
| Спонсор | Eli Lilly and Company |
|---|
| Статус | Завершено |
|---|
| Участники | 133 участн. |
|---|
| Вмешательство | LY3502970, Atorvastatin, Simvastatin, Midazolam |
|---|
| Дата начала | 12.06.2019 |
|---|
| Дата завершения | 2.11.2020 |
|---|
| Публикация результатов | 10.07.2026 |
|---|
Кратко
The main purposes of this study are to determine: * The safety of LY3502970 and any side effects that might be associated with it. * How much LY3502970 gets into the bloodstream and how long it takes the body to get rid of it. This study has 5 parts (A, B, C, D, and E). Parts A and D involve a single dose of LY3502970 and will last about 15 days. Part B and E involve multiple doses of LY3502970 and will last about 4 weeks. Part C involves two single doses of LY3502970 and will last about 29 days. Each participant will enroll in only one part. Screening must be completed within 28 days before study start. This study is for research purposes only, and is not intended to treat any medical condition.
Parts A and B: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug
Baseline through Follow-up (up to Day 42) · Participants
| Part A Placebo | 0 Participants |
|---|
| Part A 0.3 mg LY3502970 | 0 Participants |
|---|
| Part A 1 mg LY3502970 | 0 Participants |
|---|
| Part A 3 mg LY3502970 | 0 Participants |
|---|
| Part A 6 mg LY3502970 | 0 Participants |
|---|
| Part B Placebo | 0 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.